The biologics manufacturing industry has undergone several changes over the past few years starting from the development of better expression systems to modular and flexible manufacturing facilities including the emergence and use of disposables. However, there is a need for higher productivity when it comes to upstream, the need for efficient process development and cost-effective and alternative techniques when it comes to downstream processing. This apart, the industry also handles specific issues on designing facilities for flexibility and in the wake of multiple products.
The biologics industry in Asia- Pacific is estimated to be the fastest growing market in the world, for instance, Asia- Pacific accounts for alone 30% of the global biosimilar market. Low manufacturing costs and the presence of high-skilled workers at low costs are also factors that make Asia- Pacific a lucrative destination for the biologics market.
The key drivers driving the growth of the biologics industry in Asia are new- cell culture techniques, fast-track GMP facilities, flexible manufacturing facilities using disposables, attempts for continuous manufacturing, combining modular facilities and single-use and other advances in the downstream processing of biologics. However, the factors hindering the growth of the biopharmaceutical industry mainly are from the bioprocessing side including high-manufacturing complexities, expensive purification processes and other challenges across the bioprocessing value chain.
6th Annual Biologics Manufacturing Asia 2019, therefore, aims to provide a neutral platform to address the challenges faced in this sector including:
- Reducing the timelines in the upstream processing such as reducing timelines for cell-line development.
- Need for efficient screening technologies and monitoring bioprocesses in order to reduce timelines for upstream bioprocesses.
- Incorporating QbD in the early process development.
- The technical and economic viability of using a single-use biomanufacturing facility.
- Development of robust processes to suit evolving biomanufacturing needs.
- Purification process development to maximize process economy.
- Challenges in the downstream purification for highly complex molecules.
- Designing and automating quality control challenges during scale-up and process change.
- Observations in the use of disposables vs hard-piped steel containers.
- Perceived barriers to switching over from Batch to continuous manufacturing.
- Future of continuous manufacturing and the challenges faced by companies planning for the paradigm shift.
The key entities in the biologics space in Asia include: Amgen, Novartis, GlaxoSmithKline Biologicals, Pfizer, Genentech, Roche in Singapore; Samsung Bioepis, Celltrion, Green Cross, Hanhwa, Dong-A in Korea; TaiMed, PharmaEssentia, UBI, OBI in Taiwan, Biocon, Dr. Reddy’s in India; Astellas Pharma in Japan and so forth.
With a strategic location- Singapore, the biomanufacturing hub of Asia, best manufacturing facilities, strong government support, easy access from all Asian countries, technological leadership and the house of top biopharmaceutical companies developing smart manufacturing facilities for the production of biologic drugs, Singapore will indeed be an important and bright spot for such an exciting gathering.
Join us in Singapore in the foremost Biologics manufacturing industry gathering on 26 – 28 February 2019!